FDA approves Priovant's Lisraya (brepocitinib) for rare skin disease dermatomyositis

The U.S. Food and Drug Administration has cleared the first oral targeted treatment for dermatomyositis, a rare and disabling skin disorder.

The medication, brepocitinib, will be sold under the brand name Lisraya. It was originally discovered by Pfizer and later licensed to Priovant Therapeutics, a subsidiary of Roivant Sciences.

Lisraya is administered once daily and works by inhibiting the TYK2 and JAK1 enzymes, members of the Janus kinase family involved in inflammatory pathways.

The company announced a list price of $35,000 for a 30‑day supply. Roivant’s chief executive said the firm plans to emulate the commercial approaches of other biotech firms that have successfully marketed similar drugs.